September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
The top 10 findings from the RIDE/RISE trials of ranibizumab in patients with diabetic macular edema
Author Affiliations & Notes
  • Rishi P Singh
    Department of Ophthalmology, Cole Eye Institute, Cleveland, Ohio, United States
  • Lisa Tuomi
    Genentech, Inc., South San Francisco, California, United States
  • Ivaylo Stoilov
    Genentech, Inc., South San Francisco, California, United States
  • Footnotes
    Commercial Relationships   Rishi Singh, Alcon (C), Alcon (F), Apelly (F), Genentech (C), Genentech (F), Neurotech (F), Regeneron (C), Regeneron (F), Shire (C); Lisa Tuomi, Genentech (E); Ivaylo Stoilov, Genentech (E)
  • Footnotes
    Support  Genentech, Inc., South San Francisco, CA, provided support for the study and participated in the study design; conducting the study; and data collection, management, and interpretation.
Investigative Ophthalmology & Visual Science September 2016, Vol.57, No Pagination Specified. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Rishi P Singh, Lisa Tuomi, Ivaylo Stoilov; The top 10 findings from the RIDE/RISE trials of ranibizumab in patients with diabetic macular edema. Invest. Ophthalmol. Vis. Sci. 201657(12):.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : To summarize key clinically relevant lessons from 5 years of experience with ranibizumab (RBZ) in the treatment of diabetic macular edema (DME) and diabetic retinopathy (DR) in the RIDE and RISE phase 3 trials.

Methods : RIDE and RISE were randomized phase 3 trials enrolling patients with DME (N=759) to receive monthly RBZ (0.3 mg or 0.5 mg) or sham injections for 24 months. From month 25 to 36, patients randomized to RBZ continued monthly injections of their original dose, whereas patients in the sham arm crossed over to monthly 0.5 mg RBZ. After month 36, 500 patients elected to enter an open-label extension (OLE) study in which they received 0.5 mg RBZ pro re nata (PRN) based on prespecified worsening of vision or edema criteria.

Results : 1) RBZ resulted in rapid, significant, and sustained improvement of retinal thickness and vision. 2) Prior treatment with laser and/or steroids did not affect these outcomes. 3) Baseline characteristics such as HbA1c and posterior retinal nonperfusion did not affect visual acuity outcomes with RBZ; however, 4) deferral of treatment for 2 years resulted in less vision gain. 5) RBZ treatment resulted in rapid improvements in DR (significant 2-step improvement as early as 3 months, and 3-step as early as 12 months). Notably, >75% of RBZ-treated patients with moderately severe or severe nonproliferative DR experienced ≥2-step DR improvements as early as month 12. 6) RBZ delayed the time to vitreous hemorrhage and panretinal photocoagulation, and 7) significantly reduced the area of hard exudates in eyes with DME. 8) Patients who required cataract surgery during RIDE/RISE experienced a mean of ≥10-letter improvement 1 month after surgery. 9) When patients switched to less-than-monthly therapy in the OLE, mean vision and retinal thickness improvements were maintained with a mean of 3.8 annualized injections; ~25% of patients required no further injections to maintain these outcomes. 10) Improvements in DR were also durable with PRN injection.

Conclusions : In RIDE and RISE, RBZ treatment resulted in clinically relevant improvements in vision and retinal thickness regardless of baseline characteristics or previous treatment. RBZ also resulted in improvements in DR, particularly in patients at high risk of progression to proliferative DR. Improvements were maintained with less-than-monthly treatment.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.